LRP1B and melanoma: A previous melanoma study reported that LRP1B mutation was enriched in responders (34%) to immune checkpoint inhibitors (ICIs) compared with non-responders (3%) 13, which suggested LRP1B mutation may be an independent predictor for the response to ICI.